- Cytolon and T-Cell Europe agree on cooperation
- Cytolon initiates global development of DIT - Distributed-Inventory-TechnologyTM
- Cytolon joins Personalized Medicine Coalition
- Cytolon successful with second financing round
- Cytolon gains Patent for CordMatch® in Australia
- Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
- Timm Jessen Joins Cytolon’s Supervisory Board
- Cytolon Partners with iSoft for New Life Science Research Tool
- Michaela Servas joins Cytolon´s Supervisory Board
- Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
- CordMatch® goes live
- Cytolon Partners with CSC to Develop CordMatch®
- Cytolon Closes Its First Round of Financing
- Wolfgang Jünger Joins Cytolon's Supervisory Board
- Katherina Reiche, MdB, Steps Down From Cytolon's Supervisory Board to Become a Member of the Federal Government of Germany
- Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
- Cytolon Announces Cooperative Agreement with ARCWAY
- Start-up Financing Begins
- The Launching of Cytolon AG
Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
Berlin, November 2nd 2010 – Professor Joachim Wolfram Dudenhausen, co-founder and member of Cytolon´s Supervisory Board and Scientific Advisory Board, received today an Order of Merit of the Federal Republic of Germany.
Dr. Dudenhausen, professor emeritus from the Charité, the biggest and most internationally renowned German University Hospital, has made enormous contributions to the improvement of Medicine Studies in Germany. In 1989, he became Director of the Obstetrical Department at the Virchow-Klinikum from the Charité in Berlin. In 2004, he also led the Obstetrical Department of the Benjamin Franklin Campus at the same institution. From 2007 to March 31st 2010 when he became his emeritus status, he was in charge of the Obstetrical Departments from all 3 campuses of the Charité. Altogether, 60.000 children have been born in his hands.
The Senator for Education and Science said when the Order was granted, that Dr. Dudenhausen always firmly supported the need for strengthening the scientific capabilities of the faculty at the School of Medicine at the Charité.
Thomas Klein, Cytolon’s Founder and Chief Executive Officer, stated “We are very proud to have as co-founder, member of our Supervisory Board and of the Scientific Advisory Board a person that has made such a profound impact on the healthcare field”.
About Cytolon AG:
Cytolon AG is a private Company based in Berlin, Germany that has developed a proprietary, patent-pending, global, internet-based cord blood brokering platform termed CordMatch®. This platform is positioned to profit from the crossroad of the personal data and cellular therapeutic markets of regenerative medicine. Cytolon's mission is to be the world's first trusted source for getting the correct, best-matched cord blood unit (CBU) to the patient that needs it in a timely manner. An accurate cord blood matching platform is imperative as a CBU must accurately match the histocompatibility antigens and the genetic needs of the patient. Cytolon provides solutions and services for today and the future so world-wide transplant centers can talk efficiently and effectively to world-wide cord blood banks, registries, industry partners and service providers. Cytolon focuses on penetrating immediate and emerging markets in the cord blood and stem cell area. For more information, please visit the company's Web site at www.cytolon.com.
Contact:
Nina Hofle - PR
Cytolon AG
Am Karlsbad 15
10785 Berlin - Germany
phone: +49 (0) 30 2639 2880
fax: +49 (0) 30 2639 28820
e-mail: info@cytolon.com
web: www.cytolon.com